In Wednesday’s Wall Street session, Humacyte Inc (NASDAQ:HUMA) shares traded at $5.70, up 11.55% from the previous session.
HUMA stock price is now -2.34% away from the 50-day moving average and 54.52% away from the 200-day moving average. The market capitalization of the company currently stands at $678.76M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $6, H.C. Wainwright recently initiated with Buy rating for Humacyte Inc (NASDAQ: HUMA). On August 14, 2023, Piper Sandler Upgraded its previous ‘Underweight’ rating to ‘Neutral’ on the stock increasing its target price from $2.75 to quote $3.50, while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’
In other news, Dougan Brady W, Director sold 271,518 shares of the company’s stock on Jun 12 ’24. The stock was sold for $1,982,081 at an average price of $7.30. Upon completion of the transaction, the Director now directly owns 4,559,140 shares in the company, valued at $25.99 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 12 ’24, President, CEO and Director Niklason Laura E sold 271,518 shares of the business’s stock. A total of $1,982,081 was realized by selling the stock at an average price of $7.30. This leaves the insider owning 4,559,140 shares of the company worth $25.99 million. A total of 22.76% of the company’s stock is owned by insiders.
During the past 12 months, Humacyte Inc has had a low of $1.96 and a high of $9.97. As of last week, the company has a debt-to-equity ratio of 0.71, a current ratio of 8.37, and a quick ratio of 8.37. The fifty day moving average price for HUMA is $5.8759 and a two-hundred day moving average price translates $3.700975 for the stock.
The latest earnings results from Humacyte Inc (NASDAQ: HUMA) was released for 2024-03-31. The company reported revenue of $26.58 million for the quarter, compared to $22.51 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 18.06 percent.
